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Clinical Challenges and Unmet Needs in the
Management of Complicated Intra-abdominal Infections
JOHN E. MAZUSKI
ABSTRACT
Background: Management of complicated intra-abdominal infections involves invasive pro-
cedures for control of the source of the infection and antimicrobial therapy directed against
gram-negative and anaerobic pathogens. Application of these management principles to the
individual patient is essential to optimize the patient’s chances for recovery, while also avoid-
ing unnecessary therapy that may have no clinical benefits, or that may carry risk.
Methods: Based on a review of the literature, treatment guidelines, and expert opinion, the
challenges of managing patients with complicated intra-abdominal infections are summarized
using a patient stratification approach: “Lower risk” of treatment failure and death vs. “higher
risk.”
Results: Risk factors for treatment failure and death can be grouped into several categories,
including the patient’s pre-existing medical comorbidities and physiological response to the
infection, the extent of the intra-abdominal infection, and the presence of specific pathogenic
microorganisms. These latter factors may be more useful than the Acute Physiology and
Chronic Health Evaluation (APACHE) II score in evaluating specific management strategies
for patients with complicated intra-abdominal infections. The principal goal of treatment in
lower-risk patients is to avoid morbidity related to source control procedures and antimicro-
bial therapy. Limitation of the scope of source control procedures and utilization of short-du-
ration, narrow-spectrum, low-toxicity antimicrobial regimens is advisable to avoid adverse
drug reactions and selection of resistant organisms. For higher-risk patients, the goal is to de-
velop improved management modalities, so that morbidity and mortality are reduced. The
recommended approach for higher-risk patients is to identify the most appropriate source
control procedure and antimicrobial therapy, as dictated by the patient’s specific risk factors,
and to utilize the optimal tools of critical care medicine to treat these critically ill, septic pa-
tients. The emergence of bacterial resistance also must be considered when selecting antimi-
crobial therapy for both low risk and high risk patients with intra-abdominal infections. Be-
cause aminoglycoside regimens are becoming less favored, and optimal therapeutic strategies
have not been standardized, the use of new treatment options (e.g., tigecycline) may be valu-
able when managing patients with intra-abdominal infections. especially for resistant iso-
lates.
Conclusions: The management of lower-risk patients with intra-abdominal infections is dis-
tinct compared with patients at higher risk due to compromised physiological status, extent
of intra-abdominal infection, or presence of nosocomial pathogens associated with higher-
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INTRA-ABDOMINAL INFECTIONS result from thegrowth of bacteria in sterile regions of the ab-
domen such as the peritoneal cavity, the retro-
peritoneum, or solid organs, or from the 
uncontrolled overgrowth of microorganisms
within the hollow viscera, where the normal
resident flora coexists in a commensal relation-
ship with the host. These infections ordinarily
occur in association with an inflammatory
process as either cause or consequence of the
infection. As such, there is a wide variety of dis-
parate pathological processes that can be called
intra-abdominal infections, ranging from local-
ized appendicitis to the diffuse inflammation of
the abdominal cavity characterized as tertiary
peritonitis [1,2].
The term “complicated” intra-abdominal in-
fections is used to distinguish infections that re-
quire an invasive procedure for source control
from “uncomplicated” infections, which can be
treated medically without an invasive inter-
vention [1]. This distinction is most applicable
when there is a clear dichotomy in the patho-
physiology and microbiology of the infections.
Disorders such as secondary peritonitis and in-
tra-abdominal abscesses generally arise from
the resident intestinal flora and are polymicro-
bial in nature; these infections are generally
treated with an invasive procedure. In contrast,
disorders such as primary peritonitis and peri-
toneal catheter-associated infections are not
usually due to enteric pathogens, and are usu-
ally monomicrobial; such infections are usually
treated medically. However, this distinction,
having been based on operational rather than
pathophysiological differences, becomes some-
what artificial when applied to certain disor-
ders, particularly those characterized by local-
ized perforation of a hollow viscus. Thus,
perforated diverticulitis or a peri-appendiceal
phlegmon would be classified as uncompli-
cated if treated non-operatively by one practi-
tioner, but as complicated if treated surgically
by another. The lines between complicated and
uncomplicated infections are also blurred by
the use of percutaneous, radiologically-guided
procedures for both diagnostic and therapeu-
tic purposes. For instance, would the diagnos-
tic “fine-needle” aspiration of a pancreatic
phlegmon to ascertain the presence of infection
suffice for that infection, if present, to be clas-
sified as “complicated?” Alternatively, would
a drain have to be left in place for that distinc-
tion to be made? This review does not adhere
to a strict separation of intra-abdominal infec-
tions into uncomplicated and complicated va-
rieties. The discussion will focus on those in-
tra-abdominal infections treated typically by
surgeons, whether or not an initial surgical in-
tervention is performed.
The optimal treatment of patients with intra-
abdominal infections includes a source control
procedure for drainage or control of the infec-
tious focus, and adjuvant antimicrobial therapy
to treat residual infecting organisms [2–5]. In
some patients with uncomplicated intra-ab-
dominal infections, the definitive source con-
trol procedure is deferred, and there is sole re-
liance on antimicrobial agents and the host
response to control the infection. This latter ap-
proach applies to the patients described above,
who are treated nonoperatively for a phlegmon
resulting from acute diverticulitis or appen-
dicitis. Another crucial element in the care of
these patients is physiological support of organ
function during the acute phase. This includes
appropriate fluid resuscitation and other inter-
ventions needed to maintain critical perfusion
of organs being pushed to their physiological
limits by the host response to the infection [2].
Overall, the treatment paradigm of appro-
priate source control and antimicrobial therapy
has produced generally satisfactory results.
One epidemiological survey of patients with
complicated intra-abdominal infections found
an overall mortality rate of 6.0%, a postopera-
tive abscess rate of 10.2%, and a re-operation
rate of 12.5% [6]. Nonetheless, these data reflect
the outcome of a heterogeneous group of pa-
tients at variable risks of treatment failure and
death. Thus, the generally good results ob-
tained in lower-risk patients, such as the young
risk patients. Carefully designed, multidisciplinary-sponsored, clinical trials in patients with
specific clinical risk factors are needed to better assess the role of various antimicrobial reg-
imens in the treatment of higher-risk patients with intra-abdominal infections.
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patient with complicated appendicitis, con-
trasts with the much poorer results observed in
higher-risk patients, such as the elderly indi-
vidual with multiple medical comorbidities
who develops generalized peritonitis following
disruption of a colonic anastomosis.
Although stratifying the population of pa-
tients with intra-abdominal infections into
lower-risk and higher-risk patients is a simpli-
fication, it is helpful in discussing their respec-
tive, differing management challenges. The
central concept adhered to in this review is that
the management approach should reflect the
expected outcome, and that the issues in man-
agement differ between patients at lower risk
and those at higher risk. Thus, clinical investi-
gations should address different questions in
lower-risk and higher-risk patients.
The topics that will be discussed can be
grouped into three general areas: Distinguish-
ing lower-risk from higher-risk patients, and
understanding how distinct risk factors might
influence therapeutic decision-making; mini-
mizing the morbidity of the specific procedures
employed and simplifying the type of antimi-
crobial therapy used for lower-risk patients
with expected good clinical outcomes; and de-
termining how to utilize different invasive
strategies appropriately for source control and
to tailor antimicrobial therapy to the likely
pathogens that will be present in higher-risk
patients, in whom mortality is substantial.
CHARACTERIZING PATIENT RISK
Before describing separate management
strategies for lower-risk and higher-risk pa-
tients with intra-abdominal infections, it is nec-
essary to consider how to stratify patients into
these different risk categories. Stratification can
best be based on specific clinical risk factors
that predict adverse clinical outcomes, identi-
fied through the use of multivariate analyses.
For patients with complicated intra-abdominal
infections, a number of studies have identified
risk factors that are associated with treatment
failure or death.
A question that might arise is which clinical
endpoint, treatment failure or death, is more
appropriate for risk stratification. There are ad-
vantages and disadvantages to the use of either
endpoint. At first glance, mortality might seem
to be the most logical endpoint. However,
death is a relatively infrequent outcome for pa-
tients with intra-abdominal infections, espe-
cially for low risk infections, and may ulti-
mately be influenced more by factors related to
the patient’s underlying physiological condi-
tion than by factors related to the infection it-
self. Conceivably, stratification on the basis of
risk factors that predict treatment failure might
be more likely to identify a group of patients
for whom altered therapeutic interventions
would impact outcome favorably. However,
treatment failure can be a somewhat nebulous
endpoint, and needs to be described carefully.
For example, if adverse outcomes such as su-
perficial surgical site infections are included as
treatment failures in the analyses, then the
identified risk factors may pertain primarily to
these minor complications, and not to major
complications such as an intra-abdominal ab-
scess or a need for re-operation.
A number of studies [7–12] analyzing risk
factors for death and treatment failure were re-
viewed as part of the revised Surgical Infection
Society (SIS) guidelines on antimicrobial ther-
apy for intra-abdominal infections [3,4]. These
risk factors are summarized in Table 1. To a
first approximation, these data suggest that the
same general types of risk factors influence
both treatment failure and death, few of which
relate directly to the infection itself or to the
treatment modalities utilized. The Acute 
Physiology and Chronic Health Evaluation
(APACHE) II score was associated with an 
adverse outcome in all of the studies, and was
the most powerful marker of both treatment
failure and death. The APACHE II score is
based on the patient’s age, acute physiological
derangements, and the chronic health prob-
lems as determined within 24 h of the reference
time point. As such, the APACHE II score re-
flects a compilation of the severity of the in-
fection, the host response to the infection, and
the patient’s underlying comorbid medical
conditions. Several other risk factors identified
in these studies also pertained primarily to the
patients’ comorbidities. For instance, hypoal-
buminemia was found to be a risk factor for 
a poor outcome in patients with intra-abdomi-
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nal infections, and is, in fact, a factor for iden-
tifying patients at risk for an adverse outcome
following any surgical procedure [13]. None-
theless, these other risk factors are reflected to
some extent in the APACHE II score, and this
score proved to be a more consistent predictor
of outcome than any marker of the patient’s 
underlying medical condition considered sep-
arately.
There are several difficulties related to the
use of the APACHE II score for stratifying pa-
tients with intra-abdominal infections. It is
somewhat cumbersome to use, and is subject
to inter-observer variability. Furthermore, if
this score is calculated after a patient has first
been resuscitated in the emergency depart-
ment or operating room, as occurs frequently
in the patient with an intra-abdominal infec-
tion, the score is artifactually lowered. How-
ever, the major issue is whether or not the
APACHE II score provides information that is
unique to patients with intra-abdominal in-
fections, and can be used to guide specific
therapy for these patients. Given that the
APACHE II score is a general marker of criti-
cal illness, it seems possible that this score
would be more useful in determining the gen-
eral treatment approach to be followed in the
intensive care unit than in delineating specific
source control procedures or antimicrobial
regimens to be used in a given patient.
In the studies cited, a few risk factors per-
tained more to the infection, and to the treat-
ments utilized, than to the patient’s physiolog-
ical status or underlying medical condition.
These risk factors might have more direct ap-
plicability to specific therapies selected for pa-
tients with intra-abdominal infections. It is in-
teresting that the source of the infection is not
found to be an independent risk factor in these
analyses. Thus, the lower mortality rate of pa-
tients with complicated appendicitis [6] may be
related to their younger age and healthier con-
dition as to the extent of peritoneal contami-
nation, compared to patients with other types
of intra-abdominal infections.
The source of the infection may contribute
indirectly to risk, however, as an influence on
the extent of the infection. In one of the risk fac-
tor analyses, the Mannheim Peritonitis Index,
a parameter describing the extent of the intra-
abdominal infection, was found to be an inde-
pendent risk factor [10]. One observational trial
suggested limiting the duration of antimicro-
bial therapy based on the extent of the peri-
toneal infection [14], even though it did not use
the Mannheim Peritonitis Index. The use of re-
peat laparotomy or multiple reoperations has
TABLE 1. INDEPENDENT RISK FACTORS FOR MORTALITY OR TREATMENT FAILURE
Mortality (five studies) Treatment failure (two studies)
APACHE II Score# APACHE II Score*
Age* Age
Hypoalbuminemia* Hypoalbuminemia










#Identified in five studies.
*Identified in two studies.
Adapted from [4], based on [7–12].
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also been based, at least to some degree, on the
extent of the peritoneal infection [2]. Thus,
stratifying patients through the use of a repro-
ducible system to describe the extent of the in-
tra-abdominal infection could have direct utility
for future investigations into their management.
One risk factor identified as a predictor of
mortality is an unsuccessful initial operation
[12]. It is often uncertain if the initial failure is
due to technical error or due to the widespread
nature of infection. In any case, these data pro-
vide some validation for the concept that an 
optimal source control procedure is crucial to
achieving a good outcome in patients with
complicated intra-abdominal infections. The
challenge, then, is in determining how to
achieve successful initial source control, con-
sidering the multiplicity of technical ap-
proaches that are available, the lack of data 
regarding comparative efficacy of operative
procedures, and the major influences of expe-
rience and opinion in clinical surgical practice.
There is increasing recognition that patients
with intra-abdominal infections due to organ-
isms acquired in health care institutions (i.e.,
nosocomial intra-abdominal infections) are at
higher-risk for treatment failure and death. Al-
though not noted in the other multivariate
analyses, the study of Barie et al. [11] identified
a prolonged pre-study duration of hospitaliza-
tion as a risk factor for treatment failure. This
clinical parameter may be a surrogate for the
acquisition of resistant flora. Several studies
have affirmed a role of resistant microorgan-
isms in treatment failure [15–17]. In particular,
Montravers et al. [17] used a multivariate analy-
sis to show that the presence of organisms re-
sistant to the empiric antimicrobial regimen
chosen is an independent predictor of mortal-
ity in patients with postoperative peritonitis.
The choice of empiric antimicrobial therapy
may therefore play a role in determining clini-
cal outcome. Thus, stratifying patients accord-
ing to their likelihood of harboring resistant
pathogens acquired nosocomially could be an
approach to guiding the selection of specific an-
timicrobial therapy.
In summary, challenges remain in develop-
ing risk stratification of patients with compli-
cated intra-abdominal infections. Although the
APACHE II score is a powerful marker of treat-
ment failure and death, factors describing the
extent of the intra-abdominal infection and the
likelihood of resistant pathogens could poten-
tially be more useful than the APACHE II score




Lower-risk patients with community-ac-
quired intra-abdominal infections can usually
be managed successfully using the standard
approach of an appropriate source-control pro-
cedure and adjuvant antimicrobial therapy di-
rected against gram-negative Enterobacteriacae
and anaerobic pathogens. The outcome of
lower-risk patients can be inferred from the re-
sults of antibiotic registration trials carried out
in patients with complicated intra-abdominal
infections. In many of these trials, lower-risk
patients with community-acquired infections
were predominately or exclusively enrolled
and evaluated. With the exception of a few tri-
als emphasizing higher-risk patients, mortality
was nearly always less than 5% in these trials,
and was often zero. Typically, success (clinical
cure) rates ranged from 85–100% [4]. Many of
the treatment failures recorded were relatively
minor, such as the development of a superfi-
cial surgical site infection in a patient whose
surgical incision was closed primarily. Al-
though substantive treatment failures do occur
occasionally in these lower-risk patients, the
low incidence of these complications would
make it unlikely that major changes in the stan-
dard treatment approach would be rewarded
by significant improvements in outcome.
If the standard approach remains valid for
lower-risk patients with community-acquired
intra-abdominal infections, what then are the
unmet needs in managing this group of pa-
tients? Conceivably, these could be the patients
for whom less aggressive interventions might
be warranted under selected circumstances, in
order to minimize morbidity. Thus, with re-
gard to source control procedures, the chal-
lenge would be to determine if less invasive
procedures could be used, or if it is possible to
defer a definitive source control procedure en-
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tirely in selected patients. Obviously, this could
only be done if there is no compromise to the
generally good overall outcome of this group
of patients. With regard to antimicrobial ther-
apy, the goal would be to utilize a regimen that
is not only effective, but also as safe as possi-
ble. Within this context, safety applies not only
to the patient, in avoiding a potentially toxic
regimen, but also to the community at large, in
avoiding a regimen likely to encourage the de-
velopment of resistant pathogens. The ideal
regimen would also be simple to administer
and perhaps amenable for use in the outpatient
setting. The challenges of providing appropri-
ate source control and antimicrobial therapy to
lower-risk patients with community-acquired
infections will be discussed separately.
Source control for lower-risk patients with
community-acquired intra-abdominal infections
The optimal source-control procedure for pa-
tients with intra-abdominal infections has been
characterized by Marshall [2] as “drainage of ab-
scesses or infected fluid collections, debridement
of necrotic infected tissue, and definitive mea-
sures to control a source of ongoing microbial
contamination and to restore anatomy and
function.” Although source control is consid-
ered central to the treatment of complicated in-
tra-abdominal infections, and is included as a
necessary component in this definition, there
are clearly patients with intra-abdominal in-
fections who are managed successfully without
an initial source control procedure. For in-
stance, many patients with acute diverticulitis
have traditionally been managed non-opera-
tively, as have some patients with perforated
duodenal ulcers. In addition, some patients
with complicated appendicitis are being
treated with a less invasive approach, or even
an initial non-operative approach. Some of the
trends in the management of patients with ap-
pendicitis will now be detailed, as an example
of how the approach to source control in lower-
risk patients with community-acquired intra-
abdominal infections might be altered in order
to decrease morbidity.
Appendicitis is probably the most common
intra-abdominal infection treated by surgeons.
The pathophysiology of acute appendicitis has
long been assumed to be obstruction of the ap-
pendiceal lumen, with subsequent distention
and bacterial overgrowth within the lumen,
which eventually results in gangrene or perfo-
ration of the appendix. Some would argue that
acute appendicitis is not an intra-abdominal in-
fection until there is actual spread of bacteria
beyond the appendiceal wall through perfora-
tion. For purposes of this discussion, however,
all aspects of source control for appendicitis
will be considered, although issues related to
perforated and non-perforated appendicitis
will be discussed separately.
The therapy of perforated appendicitis is un-
dergoing evolution, in part because modern
imaging tools allow the extent of the infection
to be characterized as part of diagnosis. Tradi-
tionally, appendectomy had been recom-
mended for all patients with perforated ap-
pendicitis, except for those with a palpable
mass presumed due to a mature peri-appen-
diceal abscess; those patients were treated with
antimicrobial therapy and drainage of the ab-
scess, with subsequent interval appendectomy.
However, many patients with perforated ap-
pendicitis are now being diagnosed radi-
ographically; these patients do not have a pal-
pable mass or a mature abscess. Rather, they
have a peri-appendiceal phlegmon or, at most,
a small abscess in the region of the appendix.
How should a patient with a peri-appen-
diceal abscess or phlegmon be treated now that
the diagnosis can be made accurately? The
standard operative approach may necessitate a
large procedure (e.g., right hemicolectomy)
due to extensive inflammation around the ce-
cum. Initial non-operative management might
allow inflammation to subside sufficiently,
such that appendectomy would become feasi-
ble after an appropriate interval.
A number of studies have evaluated this ap-
proach to management of patients with com-
plicated appendicitis. Oliak et al. [18] reported
a series of 77 patients with perforated appen-
dicitis and no palpable mass. These patients
were initially treated nonoperatively, in many
cases without drainage of a radiologically-con-
firmed abscess. Overall, there was no differ-
ence in outcome between these patients and a
historical group of patients without a palpable
mass who were treated with an immediate op-
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erative procedure. Nonoperative management
was successful in 95% of the patients; 12% of
the patients had major complications, some of
which were the result of an interval appendec-
tomy performed subsequently. These data par-
allel those from an earlier series reported by
Hoffmann et al. [19], as well as a recent small
prospective randomized study by Kumar and
Jain [20]. However, Samuel et al. [21] published
a series of 48 children treated nonoperatively,
and found that 21% required early operative
intervention because of a failure of medical
management. They concluded that early oper-
ative management was associated with fewer
complications than was initial medical therapy.
Thus, the appropriate role of nonoperative
management of patients with perforated ap-
pendicitis is still being debated.
If non-operative management for perforated
appendicitis is utilized, what is the role of in-
terval appendectomy, which is recommended
by many surgeons, particularly pediatric sur-
geons [22]? Again, a definitive answer is not
available, due to the lack of large-scale, prospec-
tive trials. Several authors suggest that this pro-
cedure is superfluous because the incidence of
recurrent appendicitis in these patients is actu-
ally quite low, less than 20% [20,23–27]. It 
has also been suggested that recurrent appen-
dicitis, when it does occur, has a more benign
presentation than when it was diagnosed orig-
inally [24,27]. Moreover, interval appendec-
tomy has complications associated with its use
[18,26,28]. An argument in favor of interval ap-
pendectomy has been made based on the fact
that important pathological findings are often
found in the resected specimen and that an un-
derlying tumor or other important lesion might
still be present even with negative diagnostic
imaging studies [21,29,30].
If deferring or abandoning a source control
procedure for perforated appendicitis is a po-
tentially viable option, what should be the role
of appendectomy for the larger group of pa-
tients who have non-perforated appendicitis?
Clearly, the disease process is less severe in
these patients than it is in patients who have
had a perforation; yet, much of the interest in
utilizing less aggressive therapy for source con-
trol has focused only on patients who have per-
forated appendicitis. The reluctance to consider
nonoperative management for patients with
acute, non-perforated appendicitis may reflect
the longstanding concept that this pathological
process inevitably progresses to perforation
and potentially fatal peritonitis. However, this
concept is likely based more on surgical lore
than on the actual natural history of the disease
process [31].
Thus, there are few data available with re-
gard to the nonoperative management of acute,
non-perforated appendicitis. The most-cited
reference is a retrospective review of success-
ful nonoperative management in nine military
patients [32]. Additionally, a small prospective,
randomized trial by Eriksson and Granstrom
demonstrated initial success with nonoperative
management in 95% of patients with acute ap-
pendicitis, but subsequent recurrence of ap-
pendicitis in 35% [33]. Although these data sug-
gest that nonoperative management of acute
appendicitis is reasonably safe, there are ex-
tensive data documenting that appendectomy
for acute, non-perforated appendicitis is also
safe. The overall mortality over a ten-year pe-
riod in the Swedish population was 0.8/1,000
appendectomies performed [34]. The mortality
rate approached 1% only in elderly patients.
Another study from Sweden documented that
only 1.3% of patients who had undergone ap-
pendectomy underwent a subsequent surgical
procedure for adhesive small bowel obstruc-
tion after 30 years of follow-up [35]. Although
this rate was six-fold higher than that of the
control population, the increased risk was 
lowest among patients who had undergone ap-
pendectomy because of non-perforated appen-
dicitis. It is not known what the risk of subse-
quent small bowel obstruction would be in
patients with acute appendicitis managed non-
operatively.
Given these data, the traditional operative
approach to patients with acute appendicitis
seems an excellent option. What would be the
benefit of testing an option of nonoperative
management? Given that mortality and mor-
bidity related to the operative procedure is al-
ready quite low, it is likely that only outcomes
such as the cost of therapy or the time to full
recovery could be addressed feasibly. Nonethe-
less, further examination of the issue may be
worthwhile. In the United States, there has
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been a widespread increase in the use of diag-
nostic imaging techniques, particularly the use
of computerized tomographic (CT) imaging of
the abdomen, to evaluate patients with ab-
dominal pain. This use may be triggering an
operation in patients with fairly mild acute ap-
pendicitis, who, in the past, were observed clin-
ically and ultimately treated nonoperatively.
Obviously, additional data are needed to de-
termine whether or not this conjecture is true.
However, this increased use of abdominal
imaging may improve knowledge of the nat-
ural history of early appendicitis and thereby
allow objective identification of lower-risk pa-
tients who might be treated appropriately us-
ing a nonoperative approach.
Antimicrobial therapy for lower-risk patients with
intra-abdominal infections
The standard principle of antimicrobial ther-
apy for intra-abdominal infections is that the
agents used should be active against both the
aerobic/facultative anaerobic, gram-negative
bacilli and obligate anaerobic organisms that
are found as a component of the normal gut
flora, and that account for most of these
polymicrobial infections [2,3,5]. A number of
agents have been shown to be effective for
treating patients with complicated intra-ab-
dominal infections in prospective, randomized,
controlled trials. Indeed, this is one area in
which there are sufficient Class I data to de-
velop firm recommendations. Although there
are far fewer prospective data evaluating an-
timicrobial therapy for patients with intra-ab-
dominal infections treated non-operatively,
presumably these same agents would be effec-
tive for treating patients with uncomplicated
intra-abdominal infections.
Guidelines for the use of antimicrobial
agents for intra-abdominal infections have
been promulgated by both the SIS [3,4], and the
Infectious Diseases Society of America (IDSA)
[5] (Table 2). The IDSA recommendations spec-
ified a set of antimicrobials for the treatment of
patients with mild-to-moderate infections. In
contrast, the SIS guidelines did not specify
which agents to use in lower-risk patients with
community-acquired infections, but suggested
that agents with a narrower spectrum of activ-
ity, lower toxicity, and lower cost were prefer-
able for these patients. Examples cited included
anti-anaerobic cephalosporins, ampicillin/sul-
bactam, and ticarcillin/clavulanic acid, but
were not limited to those agents.
TABLE 2. RECOMMENDED ANTIMICROBIAL AGENTS FOR PATIENTS WITH INTRA-ABDOMINAL INFECTIONS






Ertapenem Cefazolin or cefuroxime plus metronidazole
Imipenem/cilastatin Ciprofloxacin, levofloxacin, moxifloxacin, or
Meropenem gatafloxacin plus metronidazole
Cefotetan
Cefoxitin
Gentamicin, tobramycin, netilmicin, or amikacin plus
an anti-anaerobe (clindamycin or metronidazole)
Cefuroxime plus metronidazole
Third/fourth-generation cephalosporin (cefotaxime,
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Beyond these general guidelines, it is diffi-
cult to derive more specific recommendations.
The available evidence only identifies antimi-
crobial regimens that are effective for the treat-
ment of patients with intra-abdominal infec-
tions, but does not provide much information
as to which agents are preferred. Given the
large number of agents available, there have
been relatively few direct comparisons. More-
over, because most registration trials have been
powered to demonstrate non-inferiority rather
than superiority, such comparisons can usually
not be made. The use of meta-analysis might
provide some insight when individual trials are
powered inadequately to detect significant dif-
ferences. For example, a recent meta-analysis
re-analyzed the role of an aminoglycoside,
used in conjunction with an anti-anaerobic
agent, for the therapy of intra-abdominal in-
fections [38]. This study concluded that amino-
glycosides were less effective than newer
agents, a finding that contradicts the concept
that these agents are the “gold standard” of an-
timicrobial therapy for intra-abdominal infec-
tions. Further, there was poor documentation
of the side effects of aminoglycosides, particu-
larly ototoxicity. A drawback to any meta-
analysis, however, is that it is dependent on the
quality of the individual studies included for
analysis. In this particular analysis, it was
found that many of the studies included in the
meta-analysis, particularly those conducted
one to two decades ago, were of low quality,
thus compromising any conclusions that could
be drawn. Moreover, single-daily-dose admin-
istration of aminoglycosides has not been eval-
uated prospectively for therapy of intra-
abdominal infections, because comparator reg-
imens used in registration trials of new agents
(which comprise the bulk of the Class I data)
must be approved by the U.S. Food and Drug
Administration (FDA). Nonetheless, a primary
role for aminoglycosides in the treatment of in-
tra-abdominal infections could be questioned
on the basis of these results.
The development of bacterial resistance is
another challenge to be faced in selecting an-
timicrobial therapy for lower-risk patients with
intra-abdominal infections. Although it is of
considerable importance in patients with noso-
comial intra-abdominal infections, which will
be considered later, this issue is also germane
to patients with community-acquired infec-
tions. Increasing resistance of Bacteroides frag-
ilis to a number of agents has been well docu-
mented, including clindamycin and anaerobic
cephalosporins, although its clinical impor-
tance is still debated [4,5]. Of more concern is
the increasing resistance of many gram-nega-
tive pathogens in general and of Escherichia coli
in particular. In a recent study from Germany,
Krobot et al. [36] found that 26% of all isolates,
26% of gram-negative isolates, and 22% of E.
coli isolates from patients with community-ac-
quired infections were resistant to some com-
monly-used antimicrobial agents. This resulted
in at least some patients receiving potentially
ineffective empiric antimicrobial therapy,
which was a risk factor for treatment failure.
Thus, even with community-acquired infec-
tions, there is no room for complacency with
regard to emerging bacterial resistance.
Certainly, it is hoped that antimicrobials un-
der development may aid in the struggle against
resistant organisms. However, there have been
few new developments in therapeutic agents for
gram-negative pathogens, although some newer
fluoroquinolones and carbapenems are now
available or undergoing clinical study. An agent
which may soon be available is tigecycline,
which is the first in a new class of antibiotics
known as glycylcyclines. This agent exhibits in
vitro activity against a variety of gram-positive,
gram-negative, and anaerobic bacteria, includ-
ing a number of resistant pathogens [37]. Dar-
tois et al. recently demonstrated non-inferiority
(i.e., therapeutic equivalence) of tigecycline
compared to imipenem-cilastatin for the treat-
ment of patients with complicated intra-ab-
dominal infections. Definitive recommenda-
tions cannot be made until the data have been
published in peer-reviewed manuscript form,
but tigecycline could represent the first new
agent from a novel antimicrobial class to be in-
troduced in recent years that can be used as
monotherapy for the treatment of patients with
intra-abdominal infections. This agent might be
useful in the treatment of patients who are al-
lergic to penicillin and other beta-lactam agents,
and those more likely to harbor resistant
pathogens because of its broad amtibacterial
spectrum of activity.
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Although newer bacterial agents may aid
temporarily in the treatment of resistant or-
ganisms, the real key is avoiding, or at least cur-
tailing, the development of these organisms.
Raymond et al. [39] have outlined a series of
steps to be taken to decrease the development
of resistant organisms in surgical patients. As
indicated previously, the choice of antimicro-
bial agents for lower-risk patients with com-
munity-acquired organisms is important in this
regard, because a narrower-spectrum agent
would be less likely to induce resistance than
would a broad-spectrum agent. Moreover, al-
though it is important that the agents are ac-
tive against the common gram-negative and
anaerobic organisms typically associated with
intra-abdominal infections, additional antimi-
crobial therapy directed against Enterococcus or
against fungal organisms is of no apparent ben-
efit for the lower-risk patient with a commu-
nity-acquired infection [3,5]. Thus, the use of
an extended-spectrum antimicrobial agent or
the addition of another antimicrobial agent to
provide such coverage will likely only lead to
the development of further resistance.
Another approach to curtailing resistance
emphasized by Raymond et al. [39] is to stop
antimicrobials once the infection is cured. Un-
fortunately, there is relatively little data avail-
able with regard to an adequate duration of
therapy for patients with intra-abdominal in-
fections. Schein et al. [14] recommended that
duration of therapy should be limited, with the
most serious infections being treated for only
three to five days, and more localized infections
(such as perforated appendicitis) being treated
for only 24–48 h. Their data indicated that such
a strategy was associated with few treatment
failures. A recent study by Gleisner et al. [40]
verified that a longer duration of antimicrobial
therapy for patients with intra-abdominal in-
fections was not associated with a decrease in
infectious complications. Both the SIS and
IDSA guidelines support limiting duration of
therapy to no more than five to seven days. De-
spite this, prolonged use of antimicrobial ther-
apy remains common. A common provision in
clinical trials in intra-abdominal infections is 
a minimum five-day course of antimicrobial
therapy, allowing up to 14 days of therapy.
Thus, the belief that prolonged antimicrobial
therapy is somehow beneficial seems to be par-
ticularly persistent.
Another concept that seems to have persisted
despite evidence to the contrary is that intra-
venous antimicrobial therapy is essential for
patients with intra-abdominal infections. An
oral regimen of ciprofloxacin plus metronida-
zole is as efficacious as an intravenous regimen
of the same agents once the patient is able 
to tolerate oral medications [4]. Oral amoxi-
cillin/clavulanic acid is another agent that has
been utilized in several trials, although its use
has not been studied as rigorously [4]. Great-
er utilization of oral antimicrobial regimens
would simplify the care of patients with intra-
abdominal infections and facilitate outpatient
treatment. However, regardless of whether oral
or intravenous antimicrobials are used, it is still
important to limit the overall duration of an-
timicrobial exposure. The total course of ther-
apy must not be lengthened by the reflexive
writing of prescriptions for a certain number of
days (usually seven days). Thus, there is a cru-
cial need to determine rigorously the optimal
duration of antimicrobial therapy for patients
with community-acquired intra-abdominal in-
fections. This information could assist in de-
lineating the role of oral antimicrobials in the
treatment of these lower-risk patients as well.
Overall, the challenges in management of
low risk patients with community-acquired 
intra-abdominal infections are primarily those
of defining and developing strategies limiting
unnecessary over-treatment of the patients,
whether it be overly aggressive surgical inter-
vention or inappropriate antimicrobial ther-
apy. However, it is important to remain vigi-
lant to the possibility of compromising patient
outcomes through utilization of more conserv-
ative treatment strategies. Changes to standard
management approaches should be under-
taken in light of carefully performed clinical




Although a primary challenge in the man-
agement of lower-risk patients with commu-
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nity-acquired intra-abdominal infections is to
decrease the potential morbidity of the inter-
ventions utilized to treat these patients, the 
primary challenge faced in the treatment of
higher-risk patients is to improve clinical out-
come, particularly mortality. Depending on the
specific criteria used to define these patients,
mortality rates are in the range of 17–32% [4].
There are many areas of controversy related to
the management of these patients, both with re-
gard to the surgical and non-surgical treat-
ments utilized, and the optimal therapeutic
strategies have not been standardized.
As discussed previously, there is no uniform
definition of what constitutes a higher-risk pa-
tient with an intra-abdominal infection. How-
ever, for the purposes of this discussion, em-
phasis will be placed on the patient at higher
risk because of: 1) compromised function of
critical organs engendered by the acute physi-
ological response to the infection and the pa-
tient’s pre-existing medical conditions; 2) the
extent of the peritoneal infection and the diffi-
culty in achieving primary source control; and
3) infection due to resistant pathogens acquired
nosocomially. Obviously, the distinction be-
tween these different sets of risk factors is
somewhat artificial, but this separation does al-
low the therapeutic approaches to be divided
into three general areas. For the first set of risk
factors, overall management strategies for the
patient with sepsis will be emphasized, for the
second set, approaches to source control will be
discussed, and for the third, the utilization of
appropriate antimicrobial therapy will be
stressed. However, these management strate-
gies clearly overlap, and no one approach can
be employed in isolation from the others. These
aims correspond broadly to the treatment goals
outlined by Marshall [2] for these patients, as
discussed next.
In discussing management strategies for
higher-risk patients with intra-abdominal in-
fections, an immediate challenge is the lack of
good clinical evidence for many of the thera-
pies utilized. There is an increasing body of ev-
idence regarding treatment of the patient with
sepsis, but very little of the data focus specifi-
cally on patients with intra-abdominal infec-
tions as a cause of sepsis. There are virtually no
prospective, randomized, controlled trials with
respect to source control procedures for higher-
risk patients with these infections. Finally, as
indicated previously, antimicrobial registration
trials have enrolled primarily lower-risk pa-
tients with community-acquired infections,
and extrapolating the results of such studies to
the treatment of higher-risk patients is prob-
lematic. Thus, most of the treatment ap-
proaches used in higher-risk patients with in-
tra-abdominal infections have never been
tested rigorously, and it is therefore difficult to
develop firm recommendations with regard to
both the general and specific therapies used.
One of the challenges for the future, then, is to
perform studies in carefully defined, higher-
risk patient subsets, so that treatment strategies
can be evaluated rigorously.
Management of sepsis in patients with 
intra-abdominal infections
In outlining management principles for pa-
tients with intra-abdominal infections, Mar-
shall emphasizes “timely hemodynamic resus-
citation and support of vital organ function” in
addition to source control and appropriate an-
timicrobial therapy [2]. Although this was not
stressed in the description of treatment of
lower-risk patients with community-acquired
infections, it is of clear importance in the man-
agement of higher-risk patients. Many of these
patients have signs of severe sepsis with com-
promised vital organ function, and some have
septic shock. The essence of these therapeutic
interventions is the timely provision of critical
care appropriate for the patient with intra-ab-
dominal sepsis.
A complete review of the treatment modali-
ties used to treat patients with sepsis is beyond
the scope of this paper. However, many of
these management principles have been out-
lined in the Surviving Sepsis Campaign, a 
series of recommendations developed by rep-
resentatives from eleven international organi-
zations, including the SIS [41]. Treatment rec-
ommendations relate to initial, goal-directed
resuscitation of the patient; the use of various
agents for hemodynamic support; strategies of
mechanical ventilation, fluid and blood prod-
uct administration; control of hyperglycemia;
the use of intravenous corticosteroids; and the
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use of activated protein C (drotrecogen alfa (ac-
tivated)), among others. Although these general
interventions will not be discussed in detail,
they should be considered of equal importance
to the specific source control procedures and
antimicrobial regimens utilized for treatment
of patients with sepsis causes by an intra-ab-
dominal infection.
Some of the general interventions used for
treating patients with sepsis may need to be
modified when applied to the higher-risk pa-
tient with an intra-abdominal infection. Be-
cause of the risk of bleeding, for instance, it is
recommended that an infusion of activated
protein C be deferred (or postponed, if begun
already) for approximately 12 h after a major
invasive procedure, such as a laparotomy
needed for source control in a patient with a
complicated intra-abdominal infection. A fur-
ther concern with the use of this agent in sur-
gical patients has also been the subject of a re-
cent FDA warning against using the drug in
postoperative patients with an APACHE II
score  25 and evidence of only single-organ
failure. Although the original data demon-
strated improved survival in patients with
sepsis and failure of two or more organs who
received activated protein C, including those
who had undergone recent surgery [42], a re-
view of more recent data in less severely ill
surgical patients with failure of only a single
organ showed that mortality was paradoxi-
cally higher. It is not known how many of
these surgical patients underwent an opera-
tion because of an intra-abdominal infection.
Nonetheless, it points to the need of careful
studies of specific interventions utilized in
higher-risk patients with intra-abdominal in-
fections.
Source control for higher-risk patients with 
intra-abdominal infections
The general principles of source control for
intra-abdominal infections, as outlined by Mar-
shall [2] and described above, apply equally to
lower-risk and higher-risk patients. As with
lower-risk patients, it would be impossible to
discuss exhaustively the options for surgical
treatment of higher-risk patients with these in-
fections. However, there are a few general
trends in the use of source control procedures
for higher-risk patients that are worthy of note.
One aspect of surgical therapy that is partic-
ularly pertinent to higher-risk patients is the
utilization of a temporizing procedure versus
a definitive one, as discussed by Fry [43]. With
higher-risk patients, a prolonged surgical pro-
cedure may compromise further an already
compromised host. In contrast, the use of tem-
porizing measures may allow the critically ill
patient to be stabilized, so that a definitive pro-
cedure may be performed under more favor-
able physiological conditions. Appropriate
temporizing procedures range from percuta-
neous drainage of the gallbladder for acute
cholecystitis, to performing a rapid bowel re-
section without re-establishment of gastroin-
testinal continuity (deferred anastomosis) in a
patient with an intestinal perforation. The use
of these temporizing procedures is analogous
to the performance of “damage control” lap-
arotomy for patients with severe abdominal
trauma and the “lethal triad” of hypothermia,
coagulopathy, and acidosis.
The use of temporizing measures may be es-
pecially pertinent to patients at higher risk be-
cause of limited physiological reserves or
compromise of vital organs. However, as in-
dicated previously, patients are also at higher
risk because of the extent of the intra-abdom-
inal infection. As already discussed, the in-
ability to achieve adequate source control,
which may itself be a consequence of the ex-
tent of the intra-abdominal infection, is a risk
factor for an adverse clinical outcome. The
management of infections developing in asso-
ciation with pancreatitis and the surgical treat-
ment of patients with severe, generalized peri-
tonitis will be discussed as an exemplar. A
description of the treatment of pancreatic in-
fections must begin with the acknowledgment
that this infection occurs late in the course of
this acute inflammatory process. Thus, some
aspects of operative and nonoperative man-
agement of patients with necrotizing pancre-
atitis may pertain to the treatment of the pa-
tient before an intra-abdominal infection is
actually present. However, it seems reason-
able to include these aspects of treatment in
the discussion, because they may have a di-
rect impact on the development of an infec-
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tion and the subsequent need for specific pro-
cedures to control the infection.
A recent international consensus conference
developed some management guidelines for
the treatment of critically ill patients with se-
vere acute pancreatitis [44]. These recommen-
dations will be taken as a starting point for this
discussion. As with most questions relating to
the appropriate therapy for higher-risk patients
with intra-abdominal infections, most of these
recommendations could not be based on large,
prospective, randomized, controlled studies.
Where such studies did exist, they actually pro-
vided somewhat conflicting data. One issue
concerns the indications and timing of surgical
procedures for the treatment of patients with
necrotizing pancreatitis. Although the evidence
was not definitive, the conference guidelines
called for pancreatic debridement/drainage
only in patients for whom the presence of an
infection had been established by either a pos-
itive culture of the area of pancreatic necrosis
obtained by fine needle aspiration, or by radi-
ographic criteria such as the presence of gas in
the area of pancreatic necrosis. The guidelines
also suggested that such procedures are opti-
mally delayed until two or three weeks after
the development of severe acute pancreatitis,
in order to allow for better demarcation of ar-
eas of necrosis. Routine debridement of pan-
creatic necrosis that is not infected was not rec-
ommended. Thus, these guidelines move away
from routine operative interventions for man-
agement of severe pancreatitis, and suggest
that aggressive source control procedures be
reserved for patients with a complicating pan-
creatic infection.
The use of prophylactic, broad-spectrum an-
tibiotics for patients with pancreatic necrosis is
an issue that generates substantial controversy.
Although this question does not relate directly
to the use of specific source control procedures,
it could have a substantial indirect impact on
the need for such procedures. The use of broad-
spectrum antimicrobial prophylaxis could be
beneficial if it prevented the development of a
pancreatic infection and thereby eliminated the
need for operative debridement. However, if
this approach failed to prevent an infection, it
could lead to the selection of resistant patho-
gens and make the infection even more diffi-
cult to treat, from both surgical and medical
perspectives [44].
Unfortunately, this is an issue for which
prospective trials have reached conflicting con-
clusions. Some earlier studies supported the
use of prophylactic, broad-spectrum, antimi-
crobial therapy in these patients, based on de-
creases in pancreatic infections, the need for op-
erative debridement, or mortality. However,
the most recent prospective trial, which was
double-blind, found no such improvement in
outcome among patients randomized to re-
ceive prophylactic ciprofloxacin and metron-
idazole compared to those randomized to re-
ceive a placebo [45]. Examining the data in
aggregate, the consensus recommendation was
that broad-spectrum, prophylactic antimicro-
bial therapy should not be administered rou-
tinely to patients with pancreatic necrosis [44].
Additional data are needed.
Another issue that generates much contro-
versy is the optimal surgical treatment of pa-
tients with severe, generalized, intra-abdomi-
nal infections, including those with persistent
or tertiary peritonitis. There has been some en-
thusiasm for routine re-exploration and ab-
dominal irrigation for patients with severe, dif-
fuse peritonitis. Wittmann et al. [46] suggested
that certain, very high-risk patients with severe
secondary peritonitis be treated with a pro-
gram of multiple planned re-laparotomies,
with the decision to re-operate being based on
the operative findings at the time of the initial
procedure. Schein [47] suggests that the best in-
dication for the use of planned re-laparotomy
is an inability to achieve source control at the
time of the initial intervention. Additional in-
dications may be for patients with poorly lo-
calized infections requiring multiple debride-
ments, and for patients with an overwhelming
amount of peritoneal contamination/infection.
There are no large prospective trials avail-
able to judge the results of routine, planned re-
laparotomy for patients with severe intra-ab-
dominal infections. Most of the studies that
have been reported are retrospective and either
uncontrolled or poorly controlled. Several have
found no improvement in clinical outcome us-
ing planned re-laparotomy [8,48,49], whereas
others have suggested a benefit to routine re-
exploration [50,51]. Obviously, this is another
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area where there is an unmet need for well-de-
signed prospective trials to evaluate this ap-
proach to these higher-risk patients.
Antimicrobial therapy for higher-risk patients
with intra-abdominal infections
For lower-risk patients with community-ac-
quired intra-abdominal infections, the specific
antimicrobial regimen selected does not appear
to have a major impact on outcome, as long as
appropriate agents are utilized. In contrast, 
antimicrobial selection may play a much more
important role in the treatment of higher-risk
patients. For instance, as already described, iso-
lation of microorganisms resistant to the initial
empiric antimicrobial regimen was identified
as a risk factor for mortality among patients
with postoperative intra-abdominal infections
[17]. Resistant microorganisms are increasingly
isolated from patients with intra-abdominal in-
fections as their length of hospitalization, and
particularly their exposure to prior antimicro-
bial therapy, increases. In patients with persis-
tent or tertiary peritonitis, the predominant
pathogens are nosocomial microorganisms,
such as Pseudomonas sp., enterococci, staphylo-
cocci, and Candida sp. [52,53], rather than the
gram-negative Enterobacteriaceae and anaerobic
organisms typical of secondary peritonitis.
The antimicrobial regimens recommended in
the SIS and IDSA guidelines for higher-risk pa-
tients with intra-abdominal infections are listed
in Table 3. These regimens include agents with
a broader spectrum of activity against gram-
negative and anaerobic organisms than those
utilized in lower-risk patients with community-
acquired infections. In general, these regimens
will provide adequate activity against most of
the common organisms isolated in higher-risk
patients, even those with intra-abdominal infec-
tions acquired nosocomially [54]. Nonetheless,
additional antimicrobial therapy should be con-
sidered for higher-risk patients who are believed
likely to be harboring resistant microorganisms.
A major challenge is identifying such patients
so that empiric antimicrobial regimens are de-
signed to have activity against an expected set
of pathogens. Some of the general principles of
antimicrobial therapy for resistant gram-nega-
tive, gram-positive, and fungal microorganisms
will now be outlined.
With respect to gram-negative organisms ac-
quired nosocomially, one problem faced in-
creasingly is the growing resistance of these or-
ganisms to many antibiotics that are available
currently. This was studied in isolates of En-
terobacteriaceae and of the non-fermentative,
gram-negative bacilli, Pseudomonas aeruginosa
and Acinetobacter baumannii, obtained over a
period of several years in the United States
[55,56]. Increasing resistance to fluoroquino-
lones, such as ciprofloxacin, was common
among all gram-negative pathogens, and there
was also increasing resistance of P. aeruginosa
to gentamicin, but not to amikacin. Another re-
cent development is the identification of strains
of P. aeruginosa that are resistant to virtually all
anti-pseudomonal antibiotics. It has been nec-
essary to resort to treatment with colistin to sal-
vage patients infected with these highly-resis-
tant strains [57].
TABLE 3. RECOMMENDED ANTIMICROBIAL AGENTS FOR PATIENTS AT HIGHER RISK DUE TO INTRA-ABDOMINAL INFECTION
SIS Guidelines [3] IDSA Guidelines [5]




An aminoglycoside plus an anti-anaerobe Aztreonam plus metronidazole
Aztreonam plus clindamycin Ciprofloxacin plus metronidazole
Ciprofloxacin plus metronidazole A third/fourth-generation cephalosporin
A third/fourth-generation cephalosporin plus metronidazole
plus an anti-anaerobe
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For patients with serious nosocomial infec-
tions due to P. aeruginosa, there is an ongoing
debate regarding the utility of treating the or-
ganism with a combination of an aminoglyco-
side and a cell wall-active agent, such as an
anti-pseudomonal penicillin, cephalosporin, or
carbapenem. Combination therapy was tested
in two clinical trials of severely ill patients with
intra-abdominal infections, but did not prove
beneficial in either [58,59]. Thus, the SIS guide-
lines recommend against the use of combina-
tion therapy for higher-risk patients with seri-
ous intra-abdominal infections.
The problem of resistance among gram-
negative organisms producing nosocomial in-
tra-abdominal infections is likely to remain a
challenge into the foreseeable future. Unfortu-
nately, there does not appear to be many new
antimicrobial agents on the horizon that are in-
trinsically active against resistant, gram-nega-
tive organisms, particularly P. aeruginosa. Thus,
measures to decrease the transmission of
highly-resistant pathogens, such as adherence
to standard infection control practices, are of
great importance. If organisms such as the pan-
resistant strains of P. aeruginosa become wide-
spread, it will greatly complicate management
of patients with nosocomial intra-abdominal
infections.
The gram-positive organisms involved in
nosocomial, intra-abdominal infections are en-
terococci and staphylococci. Although Entero-
coccus spp. are isolated occasionally as part of
the polymicrobial flora found with community-
acquired intra-abdominal infections, entero-
cocci appear to play a much greater role in 
infections acquired nosocomially. Routine
treatment of Enterococcus spp. is not recom-
mended for most patients with community-ac-
quired intra-abdominal infections, with the
possible exception of patients with serious
valvular heart disease or prosthetic valves, who
might be at risk for endocarditis in the event of
enterococcal bacteremia [60].
For higher-risk patients with nosocomial in-
tra-abdominal infections, treatment of Entero-
coccus spp. is likely of greater importance. Iso-
lation of Enterococcus spp. is more common in
patients with nosocomial intra-abdominal in-
fections [17], and their isolation is a risk factor
for treatment failure and death [61–63]. Inade-
quate empiric antimicrobial therapy is also 
a risk factor for treatment failure and death 
in patients with intra-abdominal infections
[6,17,36] and is a strong predictor of mortality
in critically ill patients with nosocomial pneu-
monia [64]. Thus, it would seem reasonable to
cover Enterococcus spp. empirically in higher-
risk patients who are likely to harbor nosoco-
mial pathogens. Such patients may include
those with prior exposure to antimicrobials and
those with complex infections of small- or
large-bowel origin. Enterococcal coverage
could be provided through the selection of
agents that have intrinsic enterococcal cover-
age, such as some penicillins and carbapenems,
or by the addition of an anti-enterococcal peni-
cillin or vancomycin to regimens that lack en-
terococcal coverage. Specific anti-enterococcal
therapy should not be continued in patients
whose intra-abdominal cultures are negative
for this organism, however.
The development of vancomycin-resistant
strains of Enterococcus, particularly E. faecium,
presents a new dilemma. Fortunately, intra-ab-
dominal infections due to this microorganism
are relatively uncommon. Several newer anti-
microbial agents, including linezolid and dap-
tomycin, are effective against vancomycin-re-
sistant enterococci (VRE). Tigecycline also has
in vitro activity against VRE [37]. Empiric ther-
apy directed against VRE has not been tested,
and cannot be recommended at the present
time. The use of agents active against VRE
should be reserved for patients who have cul-
ture-proven evidence of an infection due to this
organism.
Staphylococci are rarely isolated from pa-
tients with community-acquired intra-abdomi-
nal infections, but are isolated with increased
frequency from patients with postoperative in-
fections [17], pancreatic infections [65], or ter-
tiary peritonitis [52,53]. Both coagulase-nega-
tive and coagulase-positive staphylococci have
been recovered from patients with nosocomial
intra-abdominal infections, although the path-
ogenic role of the former has been questioned
[66]. There has been little published with re-
spect to antimicrobial therapy for patients with
intra-abdominal infections due to staphylococci.
Many of the antimicrobials recommended for
treatment of intra-abdominal infections in
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higher-risk patients, such as piperacillin/
tazobactam, carbapenems, and several third-/
fourth-generation cephalosporins have some ac-
tivity against methicillin-sensitive Staphylococ-
cus aureus. However, these agents are not gen-
erally considered first-line therapy for this
pathogen. The use of an anti-staphylococcal
penicillin would seem reasonable for patients
with serious intra-abdominal infections due to
this organism, especially if the patient had 
an associated bacteremia. For patients with a
non-anaphylactoid penicillin allergy, a first-
generation cephalosporin may be used because
the incidence of cross-reactivity is only ap-
proximately 5%. Alternatively, vancomycin
may be used.
For patients with methicillin-resistant Staphylo-
coccus aureus (MRSA), the choices are more lim-
ited. Vancomycin is still probably the first line
agent for this organism. However, there is
some evidence that linezolid is more effective
than vancomycin against this organism in crit-
ically ill patients with nosocomial pneumonia,
and in other patients with skin and soft tissue
infections [67,68]. It is unknown if this also ap-
plies to patients with intra-abdominal infec-
tions due to this organism. Quinupristin/dal-
fopristin and daptomycin are alternative
agents with activity against MRSA [69,70], but
experience in the treatment of intra-abdominal
infections with these antimicrobials is quite
limited as well. Tigecycline also has in vitro ac-
tivity against MRSA, and has been studied in
both skin and soft tissue infections and lower-
risk intra-abdominal infections.
Vancomycin is the mainstay of therapy for
patients with intra-abdominal infections due to
coagulase-negative staphylococci, if that organ-
ism is to be treated. Most isolates of coagulase-
negative Staphylococcus are resistant to anti-
staphylococcal penicillins and cephalosporins.
Although linezolid, daptomycin, and quin-
upristin/dalfopristin have activity against
these gram-positive organisms in vitro [71,72],
there is little clinical data available to make
therapeutic recommendations regarding use of
these agents for patients with intra-abdominal
infections. Tigecycline also has in vitro activity
against coagulase-negative staphylococci.
A final issue with regard to higher-risk pa-
tients with nosocomial intra-abdominal infec-
tions is the treatment of fungal pathogens, 
primarily Candida albicans. Although these
organisms are isolated with some frequency
from patients with community-acquired infec-
tions, antifungal therapy is not necessary in
that setting. Isolation of Candida spp. is pri-
marily a concern when isolated from higher-
risk patients, particularly those with nosoco-
mial intra-abdominal infections. Antifungal
therapy is not recommended for lower-risk pa-
tients with community-acquired infections,
even when abdominal cultures are positive for
Candida [3,5]. However, for higher-risk pa-
tients, and particularly those with nosocomial
intra-abdominal infections, antifungal therapy
may be warranted when this organism is re-
covered. In one prospective, randomized, con-
trolled trial [73], pre-emptive antifungal ther-
apy with fluconazole was tested in patients at
high risk for Candida infections. This study
demonstrated a decreased incidence of Candida
peritonitis in the patients given pre-emptive
fluconazole therapy. However, this approach
has yet to be adopted universally. Its utiliza-
tion is probably most appropriate at centers
where the incidence of intra-abdominal or
other infections due to Candida is high.
For patients with invasive candidal infec-
tions, several antifungal agents are now avail-
able. These include amphotericin B and its 
lipid formulations, the azoles fluconazole and
voriconazole, and the echinocandins caspofun-
gin and micafungin. The newer agents have
primarily been evaluated in patients with can-
didal blood stream infections, so their utility
for patients with candidal intra-abdominal in-
fections has to be inferred from the results ob-
tained from fungemic patients. There has been
some controversy regarding antifungal therapy
for patients with confirmed intra-abdominal in-
fections due to Candida albicans. Based on very
limited data, it had been suggested that am-
photericin B is more efficacious than flucona-
zole for treatment of these patients [74]. How-
ever, the toxicity of this agent, even in its lipid
formulations, makes the use of other agents
preferable [5,75]. It is unclear if the use of
voriconazole or caspofungin will supplant the
use of fluconazole for patients infected with
this organism. Some non-C. albicans species, es-
pecially C. glabrata and C. krusei, are less sus-
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ceptible to fluconazole. Although the use of
higher doses of fluconazole has been proposed
to treat these patients, the efficacy of this ap-
proach has not been proved [75]. These non-al-
bicans species are susceptible to both voricona-
zole and caspofungin in vitro [76,77]. Thus,
these newer agents will likely be useful in the
treatment of intra-abdominal infections due to
these resistant candidal species, although there
is little published experience to date [5,75].
Clearly, a major challenge exists in selecting
appropriate antimicrobial regimens for higher-
risk patients with intra-abdominal infections,
especially those with infections acquired noso-
comially. These regimens should be based on
the suspected pathogens in a given patient. A
better understanding of how specific risk fac-
tors influence the likelihood of infection with
specific nosocomial pathogens could thereby
facilitate the selection of antimicrobial therapy.
Ultimately, however, this knowledge will have
to be combined with knowledge of local, insti-
tutional, and unit-specific trends in the types
of nosocomial pathogens encountered and
their resistance patterns, so that an appropriate
empiric antimicrobial regimen can be tailored
to a specific patient.
What, then, is the overall management strat-
egy for the higher-risk patient with an intra-ab-
dominal infection? It would seem reasonable to
base therapy on the specific risk factors that cat-
egorize the patient as being at higher risk. For
patients with severe sepsis or septic shock, in-
terventions to maintain critical organ perfusion
and compensate for disordered organ function
would be of high priority. The guidelines out-
lined in the Surviving Sepsis Campaign guide-
line represent a reasonable initial approach to
the treatment of these patients. For patients 
at higher-risk due to the extensive nature of 
the intra-abdominal infection, source control
should be achieved in an expedient manner.
The use of temporizing measures rather than
definitive procedures may be quite important
in patients with disordered physiology. The
use of re-laparotomy, although controversial,
could be considered, particularly when it is not
possible to achieve adequate source control at
the time of the initial procedure. For patients
at higher risk due to the presence of resistant
TABLE 4. SUMMARY OF CHALLENGES IN THE MANAGEMENT OF INTRA-ABDOMINAL INFECTIONS
Identifying Patient Risk
1) What are the appropriate endpoints to use for risk factor analysis?
2) What acute physiological changes and chronic medical problems actually determine patient risk? Can a
simplified system be devised that has the same predictive value as the APACHE II score?
3) Can a uniform system, such as the Mannheim Peritonitis Index, be used to characterize the extent of the
intra-abdominal infection?
4) What characteristics can be used to identify patients harboring nosocomial pathogens?
Management of the Lower-Risk Patient
1) Which intra-abdominal infections can be treated safely without performing a primary source control
procedure?
2) Can the morbidity of source control be reduced by performing less invasive or extensive procedures without
sacrificing a good clinical outcome?
3) Are all the standard antimicrobial regimens still appropriate in the face of increasing resistance of
community-acquired pathogens?
4) What is the optimal duration of antimicrobial therapy for patients with complicated intra-abdominal
infections?
5) What is the appropriate role for oral antimicrobial agents?
Management of the Higher-Risk Patient
1) How can the general principles for the management of severe sepsis be applied to the patient with an intra-
abdominal infection? Are there any components of the Surviving Sepsis Campaign guideline that need to be
modified in treating patients with intra-abdominal infections?
2) When should temporizing procedures be utilized for source control?
3) What is the role of scheduled repeat laparotomy?
4) When should antimicrobial coverage be broadened to treat resistant, nosocomial pathogens?
5) What antifungal agents are appropriate to use in patients with intra-abdominal infections, and when?
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nosocomial pathogens, the initial empiric regi-
men should be broad in spectrum, covering the
likely resistant pathogens in a given patient,
and then narrowed as soon as possible accord-
ing to culture results. A regimen effective
against gram-negative bacilli and anaerobic
bacteria, with the specific agents selected ac-
cording to the local patterns of gram-negative
resistance, is the basis of that therapy. Cover-
age of Enterococcus spp. should be added for
patients potentially infected with that organ-
ism, and pre-emptive antifungal therapy
should also be considered in selected patients.
The utility of this approach of directing man-
agement priorities based on the specific clini-
cal risk factors of a given patient should be ver-
ified in prospective studies of higher-risk
patients with intra-abdominal infections.
CONCLUSION
In this review, an attempt has been made to
delineate some of the challenges faced in im-
proving management of patients with intra-ab-
dominal infections. This discussion has em-
phasized the concept that the needs of
lower-risk patients with community-acquired
infections are quite distinct from those of pa-
tients at higher risk due to their compromised
physiological status, the extent of their intra-
abdominal infection, or the presence of noso-
comial pathogens. Within this context, the chal-
lenges have been grouped into three general
categories: 1) facilitating the identification of
higher-risk patients; 2) providing less morbid
source control procedures and minimally toxic,
short-duration, antimicrobial regimens for
lower-risk patients; and 3) developing optimal
treatment approaches to source control and an-
timicrobial therapy for higher-risk patients. Ex-
amples of some of the challenges in these dif-
ferent areas are listed in Table 4.
Most published articles conclude with a state-
ment that further study is required, and it goes
without saying that a similar statement could
be made here. The challenges outlined in this
review are not revelatory, having been identi-
fied previously by other authors. However, an-
swers are still sought. The ultimate challenge
faced in answering these research questions is
the most difficult: How to ensure that the ap-
propriate investigations needed to answer these
research questions are actually performed. To
date, much of the high quality data on the man-
agement of intra-abdominal infections has been
generated directly or indirectly as a result of
large clinical trials funded by pharmaceutical
companies seeking approval of new antimicro-
bial agents. There is no question that these stud-
ies have expanded our knowledge base greatly
and have led to the adoption of improved ther-
apies for patients with intra-abdominal infec-
tions. Nonetheless, many of the challenges out-
lined here require studies of interventions that
are likely to be of negligible commercial value.
Unfortunately, such studies have received rela-
tively little public research support, even
though the solutions to these problems could
lead to improvements benefiting not only indi-
vidual patients, but health care as a whole. The
challenge of promoting research into the effec-
tive management of patients with intra-
abdominal infections is one that requires the co-
operation of many individuals and organiza-
tions, and will not be solved by isolated inves-
tigators working alone. For such efforts, the role
of scientific organizations such as the SIS is key.
Hopefully, these organizations will increasingly
serve not only as advocates of carefully done
clinical research, but also as the coordinators of
such investigations [78].
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